131 related articles for article (PubMed ID: 31323075)
41. A dual regimen of ritonavir/darunavir plus dolutegravir for rescue or simplification of rescue therapy: 48 weeks' observational data.
Capetti AF; Cossu MV; Orofino G; Sterrantino G; Cenderello G; De Socio GV; Cattelan AM; Soria A; Rusconi S; Riccardi N; Baldin GM; Niero FP; Barbarini G; Rizzardini G
BMC Infect Dis; 2017 Sep; 17(1):658. PubMed ID: 28964268
[TBL] [Abstract][Full Text] [Related]
42. Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results.
Reynes J; Lawal A; Pulido F; Soto-Malave R; Gathe J; Tian M; Fredrick LM; Podsadecki TJ; Nilius AM
HIV Clin Trials; 2011; 12(5):255-67. PubMed ID: 22180523
[TBL] [Abstract][Full Text] [Related]
43. HIV-RNA decay in paired blood and semen samples of subjects receiving their first dolutegravir-based ART regimen.
Fabrizio C; de Gennaro N; Volpe A; Scudeller L; Lagioia A; Falasca K; Ladisa N; Angarano G; Monno L; Saracino A
J Clin Virol; 2018 Dec; 109():45-49. PubMed ID: 30471517
[TBL] [Abstract][Full Text] [Related]
44. Cost-effectiveness of DTG + ABC/3TC versus EFV/TDF/FTC for first-line treatment of HIV-1 in the United States.
Peng S; Tafazzoli A; Dorman E; Rosenblatt L; Villasis-Keever A; Sorensen S
J Med Econ; 2015; 18(10):763-76. PubMed ID: 25934146
[TBL] [Abstract][Full Text] [Related]
45. Dolutegravir/abacavir/lamivudine versus current ART in virally suppressed patients (STRIIVING): a 48-week, randomized, non-inferiority, open-label, Phase IIIb study.
Trottier B; Lake JE; Logue K; Brinson C; Santiago L; Brennan C; Koteff JA; Wynne B; Hopking J; Granier C; Aboud M
Antivir Ther; 2017; 22(4):295-305. PubMed ID: 28401876
[TBL] [Abstract][Full Text] [Related]
46. Does ART prevent HIV transmission among MSM?
Muessig KE; Smith MK; Powers KA; Lo YR; Burns DN; Grulich AE; Phillips AN; Cohen MS
AIDS; 2012 Nov; 26(18):2267-73. PubMed ID: 22569019
[TBL] [Abstract][Full Text] [Related]
47. Choice of the initial antiretroviral treatment for HIV-positive individuals in the era of integrase inhibitors.
Alejos B; Suárez-García I; Bisbal O; Iribarren JA; Asensi V; Górgolas M; Muga R; Moreno S; Jarrín I;
PLoS One; 2019; 14(8):e0221598. PubMed ID: 31449566
[TBL] [Abstract][Full Text] [Related]
48. Comparison of nevirapine- and efavirenz-containing antiretroviral regimens in antiretroviral-naïve patients: a cohort study.
Keiser P; Nassar N; White C; Koen G; Moreno S
HIV Clin Trials; 2002; 3(4):296-303. PubMed ID: 12187503
[TBL] [Abstract][Full Text] [Related]
49. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection.
Walmsley SL; Antela A; Clumeck N; Duiculescu D; Eberhard A; Gutiérrez F; Hocqueloux L; Maggiolo F; Sandkovsky U; Granier C; Pappa K; Wynne B; Min S; Nichols G;
N Engl J Med; 2013 Nov; 369(19):1807-18. PubMed ID: 24195548
[TBL] [Abstract][Full Text] [Related]
50. Switching regimens in virologically suppressed HIV-1-infected patients: evidence base and rationale for integrase strand transfer inhibitor (INSTI)-containing regimens.
Raffi F; Esser S; Nunnari G; Pérez-Valero I; Waters L
HIV Med; 2016 Oct; 17 Suppl 5():3-16. PubMed ID: 27714978
[TBL] [Abstract][Full Text] [Related]
51. Dolutegravir: a next-generation integrase inhibitor for treatment of HIV infection.
Osterholzer DA; Goldman M
Clin Infect Dis; 2014 Jul; 59(2):265-71. PubMed ID: 24723281
[TBL] [Abstract][Full Text] [Related]
52. Effectiveness of efavirenz compared with ritonavir-boosted protease-inhibitor-based regimens as initial therapy for patients with plasma HIV-1 RNA above 100,000 copies/ml.
Imaz A; Llibre JM; Navarro J; Curto J; Clotet B; Crespo M; Ferrer E; Saumoy M; Tiraboschi JM; Murillo O; Podzamczer D
Antivir Ther; 2014; 19(6):569-77. PubMed ID: 24458091
[TBL] [Abstract][Full Text] [Related]
53. Cost-effectiveness of dolutegravir vs. efavirenz-based combined antiretroviral therapies in HIV-infected treatment-naive patients in a Nigerian treatment centre.
Isah A; Chukwu PO; Abba A; Igboeli NU; Ebere A; Omotola OF; Alozie FA; Ekwunife OI; Adibe MO
Afr Health Sci; 2023 Mar; 23(1):157-169. PubMed ID: 37545946
[TBL] [Abstract][Full Text] [Related]
54. Early clinical experience of dolutegravir in an HIV cohort in a larger teaching hospital.
Todd S; Rafferty P; Walker E; Hunter M; Dinsmore WW; Donnelly CM; McCarty EJ; Quah SP; Emerson CR
Int J STD AIDS; 2017 Oct; 28(11):1074-1081. PubMed ID: 28118801
[TBL] [Abstract][Full Text] [Related]
55. Short-term cost and efficiency analysis of raltegravir versus atazanavir/ritonavir or darunavir/ritonavir for treatment-naive adults with HIV-1 infection in Spain.
Davis AE; Brogan AJ; Goodwin B; Nocea G; Lozano V
HIV Clin Trials; 2017; 18(5-6):214-222. PubMed ID: 29210626
[TBL] [Abstract][Full Text] [Related]
56. Comparative changes of lipid levels in treatment-naive, HIV-1-infected adults treated with dolutegravir vs. efavirenz, raltegravir, and ritonavir-boosted darunavir-based regimens over 48 weeks.
Quercia R; Roberts J; Martin-Carpenter L; Zala C
Clin Drug Investig; 2015 Mar; 35(3):211-9. PubMed ID: 25637061
[TBL] [Abstract][Full Text] [Related]
57. A model-based comparative meta-analysis of the efficacy of dolutegravir-based and efavirenz-based regimens in HIV-infected patients.
Ota R; Ishii H; Tsuda M; Higuchi Y; Yamashita F
J Infect Chemother; 2019 Sep; 25(9):687-694. PubMed ID: 30982724
[TBL] [Abstract][Full Text] [Related]
58. Factors predictive of successful darunavir/ritonavir-based therapy in highly antiretroviral-experienced HIV-1-infected patients (the DARWEST study).
Delaugerre C; Buyck JF; Peytavin G; Viard JP; Chaix ML; Zucman D; Mortier E; Blanche S; Rouveix E; Force G; Aegerter P; de Truchis P
J Clin Virol; 2010 Mar; 47(3):248-52. PubMed ID: 20097121
[TBL] [Abstract][Full Text] [Related]
59. Virologic and immunologic effectiveness of tipranavir/ritonavir (TPV/r)- versus darunavir/ritonavir (DRV/r)-based regimens in clinical practice.
Antoniou T; Raboud JM; Diong C; Su D; Dewhurst N; Buckley V; Kovacs C; Rachlis A; Brunetta J; Smith G; Gough K; Fletcher D; Loutfy MR
J Int Assoc Physicians AIDS Care (Chic); 2010; 9(6):382-9. PubMed ID: 21138833
[TBL] [Abstract][Full Text] [Related]
60. Real-life study of dual therapy based on dolutegravir and ritonavir-boosted darunavir in HIV-1-infected treatment-experienced patients.
Jabłonowska E; Siwak E; Bociąga-Jasik M; Gąsiorowski J; Kalinowska A; Firląg Burkacka E; Wójcik-Cichy K; Piątek A; Cielniak I; Horban A
PLoS One; 2019; 14(1):e0210476. PubMed ID: 30653541
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
